Workflow
近三日获1.8亿元资金净流入,港股创新药ETF(159567)回调跌超2%,盘中溢价明显
2 1 Shi Ji Jing Ji Bao Dao·2025-06-26 02:22

Group 1 - The Hang Seng Index fell by 0.79% as of June 26, with the Hong Kong pharmaceutical sector experiencing a pullback, and the CSI Hong Kong Innovation Drug Index (987018.SZ) dropping over 3% at one point [1] - Among the index constituents, Dongyangguang Changjiang Pharmaceutical rose over 2%, while Kangzhe Pharmaceutical, Lepu Biopharma-B, and Fosun Pharma declined by 0.17%, 1.04%, and 1.23% respectively [1] - The Hong Kong Innovation Drug ETF (159567) also saw a decline of over 2%, with a trading volume exceeding 700 million yuan and a significant premium rate of 0.7% [1] Group 2 - AstraZeneca's new weight management drug AZD6234 has been approved for clinical trials in China, targeting overweight or obese adults with at least one obesity-related comorbidity [2] - AZD6234 is a peptide drug designed for weekly subcutaneous injection, currently undergoing Phase 2b clinical trials internationally [2] - Tianfeng Securities indicates that Chinese innovative drugs are expected to continue achieving domestic innovation due to policy support and enhanced product capabilities, despite foreign companies holding a significant portion of the market [2]